Separately, Zacks Investment Research cut shares of Gamida Cell from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.67.
Shares of NASDAQ:GMDA traded down $0.03 during trading on Thursday, reaching $3.62. The stock had a trading volume of 5,189 shares, compared to its average volume of 23,902. Gamida Cell has a 52 week low of $3.60 and a 52 week high of $15.41. The firm has a 50-day simple moving average of $5.17. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.52 and a quick ratio of 6.52. The company has a market cap of $87.68 million and a PE ratio of -0.34.
Several institutional investors have recently modified their holdings of GMDA. Millennium Management LLC acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $210,000. FMR LLC acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $1,243,000. Norges Bank acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $88,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Gamida Cell in the first quarter valued at approximately $53,000. 1.72% of the stock is owned by institutional investors and hedge funds.
Gamida Cell Company Profile
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Featured Story: Discover Your Risk Tolerance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.